Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 1897-1906

  Eschenauer, Gregory A ^a   Nguyen, M Hong ^b   Shoham, Shmuel ^c   Vazquez, Jose A ^d,m   Morris, Arthur J ^e   Pasculle, William A ^a   Kubin, Christine J ^f   Klinker, Kenneth P ^g   Carver, Peggy L ^h   Hanson, Kimberly E ⁱ   Chen, Sharon ^j   Lam, Simon W ^k   Potoski, Brian A ^a   Clarke, Lloyd G ^a   Shields, Ryan K ^b   Clancy, Cornelius J ^b,l  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j WESTMEAD HOSPITAL   (Australia)

^k LERNER RESEARCH INSTITUTE   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m MEDICAL COLLEGE OF GEORGIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; HOSPITAL; HUMAN; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CANDIDA; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS;

EID: 84896994835     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02163-13     Document Type: Article

References (18)

1. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. 2013. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob. Agents Chemother. 57:3528-3535. http://dx.doi.org/10.1128/AAC.00136-13.
2. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
3. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Subcommittee on Antifungal Susceptibility Testing of the ESCMID-European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405. http://dx.doi.org/10.1111/j.1469-0691.2007.01935.x.
5. Arendrup MC, Rodriguez-Tudela JL, Lass-Flörl C, Cuenca-Estrella M, Donnelly JP, Hope W, European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing. 2011. EUCAST technical note on anidulafungin. Clin. Microbiol. Infect. 17:E18-E20. http://dx.doi.org/10. 1111/j.1469-0691.2011.03647.x.
6. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/ j.1469-0691.2012.03880.x.
7. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176. http://dx.doi.org/10.1016/j.drup.2011.01.004.
8. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10. 1128/AAC.01519-13.
9. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. http://dx.doi.org/10.1128/CMR.00029-06. (Pubitemid 46167771)
10. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. 2013. Anidulafungin and micafungin minimum inhibitory concentration breakpoints are superior to caspofungin for identifying FKS mutant Candida glabrata and echinoncandin resistance. Antimicrob. Agents Chemother. 57:6361-6365. http://dx.doi.org/10.1128/AAC.01451-13.
11. Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A, Ramani R. 2012. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp. using new clinical breakpoints and epidemiological cutoff values. Diagn. Microbiol. Infect. Dis. 73:365-368. http://dx.doi.org/10.1016/j.diagmicrobio.2012.05.008.
12. Arendrup MC, Pfaller MA, Danish Fungaemia Study Group. 2012. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised caspofungin CLSI breakpoints. Antimicrob. Agents Chemother. 56:3965-3968. http://dx.doi.org/10.1128/AAC.00355-12.
13. Arendrup MC, Garcia-Effron G, Buzina W, Mortensen KL, Reiter N, Lundin C, Elvang Jensen H, Lass-Florl C, Perlin DS, Bruun B. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implications for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193. http://dx.doi.org/10.1128/ AAC.01292-08.
14. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369- 11.
15. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
16. Arendrup CA, Garcia-Effron G, Lass-Florl C, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest Media. Antimicrob. Agents Chemother. 54:426-439. http://dx.doi.org/10.1128/AAC.01256-09.
17. Andes DR, Safda N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ, Mycoses Study Group. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54:1110-1122. http://dx.doi.org/10.1093/cid/cis021.
18. Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields RK, Clancy CJ, Nguyen MH, Lam SW. 2013. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. J. Antimicrob. Chemother. 68:922-926. http://dx.doi.org/10.1093/jac/dks482.